Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

How can clinical trial participants be prevented from recording information inaccurately? One solution for pharmaceutical ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...

Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.